NCT05815212View on ClinicalTrials.gov

Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)

CompletedOBSERVATIONAL
Enrollment

87

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

April 4, 2022

Study Completion Date

April 4, 2022

Conditions
Diabetic Macular Edema
Trial Locations (1)

Unknown

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY